Kristiansen J
The National Institute of Occupational Health, Copenhagen, Denmark.
Clin Chem Lab Med. 2001 Oct;39(10):920-31. doi: 10.1515/CCLM.2001.148.
There is a growing pressure on clinical chemistry laboratories to conform to quality standards that require the evaluation and expression of the uncertainty of results of measurement. Nevertheless, there is some reluctance to accept the uncertainty concept in the analytical community due to difficulty in evaluating uncertainty in practice. For example, often the uncertainty of some uncertainty components is not known very well in clinical chemistry measurements, such as those associated with matrix effects or with the values of the calibrators. Moreover, it is not clear how to interpret uncertainty in relation to diagnostic criteria, reference ranges and other decision limits in clinical chemistry practice. Hence, the value of reporting the uncertainty of the measurement result is not obvious. In this paper it is suggested a relatively simple, logical procedure for evaluating measurement uncertainty based on the principles in the Guide for the Expression of Uncertainty of Measurement (GUM). The measurement process is partitioned into elements that are well known to the analyst, namely sampling, calibration, and analysis. The corresponding model function expresses the result of a measurement as the value obtained by the analytical procedure multiplied by the correction factors for sampling bias, for bias caused by the calibrators, and for other types of bias. Under normal conditions, when the measurement procedure is validated and corrected for all known bias, the expected value of each correction factor is one. The uncertainty that remains with regard to sampling, manufacturing of calibrators and other types of bias is combined with the analytical imprecision to yield a combined uncertainty of a result of measurement. The advantages of this approach are: (i) Data from the method validation, internal quality control and from participation in external quality control schemes can be used as input in the uncertainty evaluation process. (ii) The partition of the measurement into well-defined tasks highlights the different responsibilities of the clinical chemistry laboratory and of the manufacturer of reagents and calibrators. (iii) The approach can be used to harmonize the uncertainty evaluation process, which is particularly relevant for laboratories seeking accreditation under ISO 17025. The application of the proposed model is demonstrated by evaluating the uncertainty of a result of a measurement of prolactin in human serum. In the example it is shown how to treat the uncertainty associated with a calibrator supplied with a commercial analytical kit, and how to evaluate the uncertainty associated with matrix effects.
临床化学实验室面临着越来越大的压力,要符合要求评估和表述测量结果不确定度的质量标准。然而,由于在实际中评估不确定度存在困难,分析界对接受不确定度概念仍有些不情愿。例如,在临床化学测量中,一些不确定度分量的不确定度往往不太清楚,比如与基质效应或校准品值相关的那些。此外,在临床化学实践中,关于如何根据诊断标准、参考范围和其他决策限来解释不确定度并不明确。因此,报告测量结果不确定度的价值并不明显。本文提出了一种基于《测量不确定度表示指南》(GUM)中的原则来评估测量不确定度的相对简单、合乎逻辑的程序。测量过程被划分为分析人员熟知的要素,即采样、校准和分析。相应的模型函数将测量结果表示为分析程序获得的值乘以采样偏差、校准品引起的偏差以及其他类型偏差的校正因子。在正常情况下,当测量程序针对所有已知偏差进行验证和校正时,则每个校正因子的预期值为1。与采样、校准品制造和其他类型偏差相关的剩余不确定度与分析不精密度相结合,得出测量结果的合成不确定度。这种方法的优点包括:(i)方法验证、内部质量控制以及参与外部质量控制计划的数据可作为不确定度评估过程的输入。(ii)将测量划分为明确的任务突出了临床化学实验室以及试剂和校准品制造商的不同职责。(iii)该方法可用于协调不确定度评估过程,这对于寻求ISO 17025认可的实验室尤为相关。通过评估人血清中催乳素测量结果的不确定度来演示所提出模型的应用。在该示例中,展示了如何处理与商业分析试剂盒提供的校准品相关的不确定度,以及如何评估与基质效应相关的不确定度。